{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:43Z","timestamp":1740107443764,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00280-018-3568-x","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:26:42Z","timestamp":1523406402000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study"],"prefix":"10.1007","volume":"81","author":[{"given":"Chu","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-9881","authenticated-orcid":false,"given":"Michitaka","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,11]]},"reference":[{"issue":"7","key":"3568_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","volume":"22","author":"A Grothey","year":"2004","unstructured":"Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209\u20131214. \n                    https:\/\/doi.org\/10.1200\/jco.2004.11.037","journal-title":"J Clin Oncol"},{"issue":"16","key":"3568_CR2","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u20132947","journal-title":"J Clin Oncol"},{"issue":"1","key":"3568_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136\u2013147. \n                    https:\/\/doi.org\/10.1200\/jco.2000.18.1.136","journal-title":"J Clin Oncol"},{"issue":"9209","key":"3568_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041\u20131047","journal-title":"Lancet"},{"issue":"2","key":"3568_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237. \n                    https:\/\/doi.org\/10.1200\/jco.2004.05.113","journal-title":"J Clin Oncol"},{"issue":"14","key":"3568_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D\u2019Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0805019","journal-title":"N Engl J Med"},{"issue":"23","key":"3568_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342. \n                    https:\/\/doi.org\/10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"issue":"3","key":"3568_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 24(3):394\u2013400. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.03.0106","journal-title":"J Clin Oncol"},{"issue":"9","key":"3568_CR9","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/sj.bjc.6603095","volume":"94","author":"M Mabro","year":"2006","unstructured":"Mabro M, Artru P, Andre T, Flesch M, Maindrault-Goebel F, Landi B, Lledo G, Plantade A, Louvet C, de Gramont A (2006) A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 94(9):1287\u20131292. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6603095","journal-title":"Br J Cancer"},{"issue":"9","key":"3568_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853\u2013860. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(10)70181-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"3568_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10147-004-0381-9","volume":"9","author":"W Arai","year":"2004","unstructured":"Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T (2004) Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 9(3):143\u2013148. \n                    https:\/\/doi.org\/10.1007\/s10147-004-0381-9","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"3568_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10147-010-0036-y","volume":"15","author":"K Sakuma","year":"2010","unstructured":"Sakuma K, Hosoya Y, Arai W, Haruta H, Ui T, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Hyodo M, Nagai H, Yasuda Y, Shirasaka T (2010) Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 15(2):166\u2013171. \n                    https:\/\/doi.org\/10.1007\/s10147-010-0036-y","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"3568_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10147-014-0699-x","volume":"20","author":"T Komura","year":"2015","unstructured":"Komura T, Miura K, Shirasaka T, Ohnuma S, Shimada M, Kajiwara T, Fujishima F, Philchenkov A, Nakagawa K, Kudoh K, Haneda S, Toshima M, Kohyama A, Musha H, Naitoh T, Shibata C, Unno M (2015) Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. Int J Clin Oncol 20(1):117\u2013125. \n                    https:\/\/doi.org\/10.1007\/s10147-014-0699-x","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"3568_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford: 1990) 45(2):228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer (Oxford: 1990)"},{"issue":"2","key":"3568_CR15","first-page":"119","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull B (1998) Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions. Am Stat 52(2):119\u2013126","journal-title":"Am Stat"},{"issue":"12","key":"3568_CR16","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006\u20132012. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","journal-title":"J Clin Oncol"},{"issue":"10","key":"3568_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jjco\/hyq069","volume":"40","author":"T Doi","year":"2010","unstructured":"Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H (2010) Phase I\/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40(10):913\u2013920. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyq069","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"3568_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bjc.2011.201","volume":"105","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105(1):58\u201364. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.201","journal-title":"Br J Cancer"},{"key":"3568_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0911-7","author":"C Matsuda","year":"2015","unstructured":"Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H (2015) Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (the ORION Study). Int J Clin Oncol. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0911-7","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"3568_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjc.6604271","volume":"98","author":"Y Yamada","year":"2008","unstructured":"Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y (2008) Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98(6):1034\u20131038. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6604271","journal-title":"Br J Cancer"},{"issue":"3","key":"3568_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-014-2672-9","volume":"75","author":"Y Sato","year":"2015","unstructured":"Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J (2015) A dose-escalation study of oxaliplatin\/capecitabine\/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 75(3):587\u2013594. \n                    https:\/\/doi.org\/10.1007\/s00280-014-2672-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"3568_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2014-0159","volume":"19","author":"Y Hamamoto","year":"2014","unstructured":"Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y (2014) A phase I\/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). Oncologist 19(11):1131\u20131132. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2014-0159","journal-title":"Oncologist"},{"issue":"1\u20132","key":"3568_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000328739","volume":"80","author":"Y Komatsu","year":"2011","unstructured":"Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M (2011) Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80(1\u20132):70\u201375. \n                    https:\/\/doi.org\/10.1159\/000328739","journal-title":"Oncology"},{"issue":"4","key":"3568_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s10637-011-9743-0","volume":"30","author":"Y Yamada","year":"2012","unstructured":"Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y (2012) Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Investig New Drugs 30(4):1690\u20131696. \n                    https:\/\/doi.org\/10.1007\/s10637-011-9743-0","journal-title":"Investig New Drugs"},{"issue":"5","key":"3568_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10147-015-0791-x","volume":"20","author":"T Kajiwara","year":"2015","unstructured":"Kajiwara T, Miura K, Ohnuma S, Shimada M, Komura T, Toshima M, Kohyama A, Kudoh K, Haneda S, Musha H, Naitoh T, Shirasaka T, Unno M (2015) Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. Int J Clin Oncol 20(5):913\u2013921. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0791-x","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"3568_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2013.50.8077","volume":"32","author":"PM Hoff","year":"2014","unstructured":"Hoff PM, Saragiotto DF, Barrios CH, del Giglio A, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella Mdo S, Passos VQ, Chinen RN, van Eyll B (2014) Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol 32(10):1006\u20131011. \n                    https:\/\/doi.org\/10.1200\/jco.2013.50.8077","journal-title":"J Clin Oncol"},{"issue":"3","key":"3568_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00520-014-2402-1","volume":"23","author":"BK Kee","year":"2015","unstructured":"Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M, Glover K, Jones D, Wen S, Fisch MJ (2015) A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 23(3):661\u2013670. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2402-1","journal-title":"Support Care Cancer"},{"issue":"4\u20136","key":"3568_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000086971","volume":"68","author":"M Karthaus","year":"2005","unstructured":"Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J, Braumann D, Behrens R, Behringer D, Kindler M, Messmann H, Boeck HP, Greinwald R, Kleeberg U (2005) Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 68(4\u20136):326\u2013332. \n                    https:\/\/doi.org\/10.1159\/000086971","journal-title":"Oncology"},{"issue":"3","key":"3568_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ctim.2015.03.008","volume":"23","author":"M Mego","year":"2015","unstructured":"Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, Lagin A, Svetlovska D, Spanik S, Zajac V, Mardiak J, Drgona L (2015) Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med 23(3):356\u2013362. \n                    https:\/\/doi.org\/10.1016\/j.ctim.2015.03.008","journal-title":"Complement Ther Med"},{"issue":"8","key":"3568_CR30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6603990","volume":"97","author":"P Osterlund","year":"2007","unstructured":"Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97(8):1028\u20131034. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6603990","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3568-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T19:04:15Z","timestamp":1554923055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3568"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3568-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,4,11]]},"assertion":[{"value":"14 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS has received honoraria from Tsumura, Chugai Pharmaceutical, and consulting fee from Takeda Pharmaceutical. HM has received consulting fee from Takeda Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical and Taiho Pharmaceutical. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}